These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1119 related items for PubMed ID: 23095323

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Chu CT, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK.
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [Abstract] [Full Text] [Related]

  • 3. ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
    Alves-Fernandes DK, Oliveira ÉA, Faião-Flores F, Alicea-Rebecca G, Weeraratna AT, Smalley KSM, Barros SBM, Maria-Engler SS.
    Pharmacol Res; 2019 Mar; 141():63-72. PubMed ID: 30550954
    [Abstract] [Full Text] [Related]

  • 4. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA.
    Clin Cancer Res; 2015 Jul 15; 21(14):3140-8. PubMed ID: 25609064
    [Abstract] [Full Text] [Related]

  • 5. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A.
    Oncotarget; 2016 Jan 26; 7(4):3947-65. PubMed ID: 26678033
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
    Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA.
    Pigment Cell Melanoma Res; 2012 Mar 26; 25(2):248-58. PubMed ID: 22171948
    [Abstract] [Full Text] [Related]

  • 8. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F.
    Clin Cancer Res; 2017 Oct 15; 23(20):6203-6214. PubMed ID: 28724666
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R, Dermatology Cooperative Oncology Group (DeCOG).
    Eur J Cancer; 2014 Jan 15; 50(2):406-10. PubMed ID: 24183461
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
    Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE.
    Cancer Discov; 2020 Feb 15; 10(2):254-269. PubMed ID: 31796433
    [Abstract] [Full Text] [Related]

  • 13. PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.
    Audrito V, Serra S, Stingi A, Orso F, Gaudino F, Bologna C, Neri F, Garaffo G, Nassini R, Baroni G, Rulli E, Massi D, Oliviero S, Piva R, Taverna D, Mandalà M, Deaglio S.
    Oncotarget; 2017 Feb 28; 8(9):15894-15911. PubMed ID: 28199980
    [Abstract] [Full Text] [Related]

  • 14. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
    Schaper-Gerhardt K, Okoye S, Herbst R, Ulrich J, Terheyden P, Pföhler C, Utikal JS, Kreuter A, Mohr P, Dippel E, Satzger I, Sucker A, Schadendorf D, Ugurel S, Gutzmer R.
    Eur J Cancer; 2018 Jan 28; 88():67-76. PubMed ID: 29195116
    [Abstract] [Full Text] [Related]

  • 15. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, Meier F.
    Pharmacol Res; 2018 Oct 28; 136():151-159. PubMed ID: 30145328
    [Abstract] [Full Text] [Related]

  • 16. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
    Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford RF, Rizos H.
    Mol Oncol; 2014 May 28; 8(3):544-54. PubMed ID: 24476679
    [Abstract] [Full Text] [Related]

  • 17. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
    Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P.
    PLoS One; 2015 May 28; 10(4):e0123410. PubMed ID: 25844720
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.
    Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, Lu Y, Mills GB, Field J, Villanueva J, Xu X, Herlyn M, Guo W.
    Oncogene; 2021 Sep 28; 40(37):5590-5599. PubMed ID: 34304249
    [Abstract] [Full Text] [Related]

  • 20. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
    Bonfill-Teixidor E, Iurlaro R, Handl C, Wichmann J, Arias A, Cuartas I, Emmenegger J, Romagnani A, Mangano L, Lorber T, Berrera M, Godfried Sie C, Köchl F, Eckmann J, Feddersen R, Kornacker M, Schnetzler G, Cicuendez M, Cordero E, Topczewski TE, Ferres-Pijoan A, González J, Martínez-Ricarte F, Muñoz-Couselo E, Tabernero J, Bischoff JR, Pettazzoni P, Seoane J.
    Cancer Res; 2022 Jul 18; 82(14):2552-2564. PubMed ID: 35584009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.